Protox Therapeutics Inc. (TSX-V: PRX) today
announced the enrollment and successful dosing of the first patient in a
Phase I clinical study evaluating their lead drug, PRX302, to treat localized
recurrent prostate cancer. PRX302 is a targeted pro-drug that turns into a
potent anti-cancer agent once activated by the enzyme, prostate specific
antigen (PSA), produced in high levels by prostate cancer and hyperplastic
prostate cells. Once activated, PRX302 destroys the cells by punching holes in
the cell membrane.
